Browse by author
Lookup NU author(s): Fiona Errington,
Dr Elaine Willmore,
Dr Michael Tilby,
Professor Caroline Austin
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Murine transgenic cell lines lacking DNA topoisomerase II (topo II)β have been used to assess the importance of topo IIβ as a drug target. Western blot analysis confirmed that the topo IIβ -/- cell lines did not contain topo II/3 protein. In addition, both the topo IIβ +/+ and topo IIβ -/- cell lines contained similar levels of topo IIα protein. The trapped in agarose DNA immunostaining assay (TARDIS) was used to detect topo IIα and β cleavable complexes in topo IIβ -/- and topo IIβ +/+ cells. These results show that both topo IIα and β are in vivo targets for etoposide, mitoxantrone, and amsacrine (mAMSA) in topo IIβ +/+ cells. As expected, only the α-isoform was targeted in topo IIβ -/- cells. Clonogenic assays comparing the survival of topo IIβ -/- and topo IIβ +/+ cells were carried out to establish whether the absence of topo IIβ caused drug resistance. Increased survival of topo II -/- cells compared with topo IIβ +/+ cells was observed after treatment with amsacrine (mAMSA), methyl N-(4'- [9-acridinylamino]-2-methoxyphenyl) carbamate hydrochloride (AMCA), methyl N- (4'-[9-acridinylamino]-2-methoxyphenyl)carbamate hydrochloride (mAMCA), mitoxantrone, and etoposide. These studies showed that topo IIβ -/- cells were significantly more resistant to mAMSA, AMCA, mAMCA, and mitoxantrone, than topo IIβ +/+ cells, indicating that topo IIβ is an important target for the cytotoxic effects of these compounds.
Author(s): Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley B, Austin CA
Publication type: Article
Publication status: Published
Journal: Molecular Pharmacology
Print publication date: 01/01/1999
ISSN (print): 0026-895X
ISSN (electronic): 1521-0111
Publisher: American Society for Pharmacology and Experimental Therapeutics
PubMed id: 10570059